Recent evidence from both clinical and preclinical studies indicates that Il-33 and its receptor ST2 (suppression of tumorigenicity 2) are involved in the pathogenesis of chronic kidney disease, systemic lupus nephritis, and acute kidney injury34. Here, IL33 is linked to chronic kidney disease.